9:ooAM – 10/1/2014: Partnering I @14th Global Partnering & Biotech Investment, Congress Center Basel – SACHS Associates, London
Reporter: Aviva Lev-Ari, PhD, RN
Real Time Media Conference Coverage – Business and Scientific Channels by: https://pharmaceuticalintelligence.com
Co-Chaired by:
- Fintan Walton, CEO and Founder, PharmaVentures
– Strategies and Tactics
- Stephanie Leouzon, Principal, Torreya Partners
Panelists Partnering I:
- Andrew Mackie, Global External R&D, Eli Lilly and Company
– Innovations with researches, series of molecule, prescreening, if interesting found, licensing agreement, engagement on Chemistry
– technology may be too early for the company, 20% funding from fund, advice as well as advice on coumpound of interest at the company
– pathways for selection, pipeline
– Pre clinical innovation – integration of Molecule the study is done.
– process id length, negotiation takes years
- Jason Coloma, Global Head Venture & Innovation at Roche Partnering, F. Hoffmannn La Roche
– Oncology is Prime, structural include Genetech, contributes on Research, Access a and speed, business development in therapeutics. Venture Innovation is discovering pipeline, crossroad, partnership with VC, diversify biology, VC and non investment in area unless internal capabilities are existing,
– Which approach you are more proud of: early stage innovation, BIOTECH & VC, partnerships, value from working with Academics, Story of Scientist and building the relations takes time
- Johan Verbeeck, Senior Director Alliance Management, J&J Innovation Center, Janssen Pharmaceutical of J&J
– Diagnostics, Pharmaceutical, growth from acquisition, 54% of pipeline are from external. Access to assets among big Pharma
– SF, Shanghai, Boston,
– presence and responsiveness and why the deal is not right
– Government and internal R&D are very important, internal R&D involves making calls on new directions
– North America is different that Europe, great good science in Europe, no risk taking. In USA, Kendall Square — risk is been taken 5 start ups over night.
– Question from the Floor: Scouts in Europe working on J&J Innovations from Spain to 8 countries in Europe,
– Satellite in Israel and in Moscow
– there are institutes for Drug Discoveries – collaboration with Pharma
– 25% from Academia, 50% partnership with industry San Diego is a Hub
– Signing deals series of approval, university has funds and Pharma provide funds
– Some scientists can’t answer questions from Pharma
- Frank Grams, VP, Head R&D Alliance Management & Contracting, Sanofi
– Sonafi more than 300 acquisitions, different company at present, process of integration, alliance with other industry and study from other Pharma, selling the opportunity in house, all Pharmaceutical in Sanofi: Diabetes, CVD, Opthalmonogy, OTC, Generic,
– Diabetes focus with therapeutics areas,investment in early stage all spectrum, academic alliance, pipeline, external sources, highly dependent on external world
– constant improvement
– right people to delegate, scouts, lawyer, communication – How do you create links to R&D? Structure organizational to allow for buyout.
– 80 and more collaborations, agreement with Academia in the US – outocme was almost zero, at present academic alliances must fit with strategy of Sanofi, look at it as a portfolio, getting out must be an option
- Paola Casarosa, Corp. Vice President of Therapeutic Alliances and astrategic Partnerships, Boehringer Ingelheim
– CNS, Oncology, Immunology – How the portfolio looks and How to achieve,
– Internal vs. External — not invented here — not acceptable, integration of internal and external is in implementation, Fundamental in scouting, engagement with academia, BD acts Globally Boston, CHina, Japan, Deals – early partnering is very important to reach agreement early on
– colliding new target concepts, major effort on scouting in Academia, they are interested in external relation, No IP driven compound, but idea with innovation solution, investing in opportunities allowing foot in the door as first mover advantage
– depression, circuits of Brain — innovation
– people level very important
– Alliance reporting to R&D – growing wiht project, supporter of this integration
– Japan support of Academia and Industry at the national level
- Tomas Landh, Director, Strategy and Innovation Sourcing, Novo Nordisk
– new perspective on Diabetes and Obesity, Retinopathie, Hemopealia, Growth Disorder, advice on early stage research, establish repationship with PI and where PI, postdocs are moving. 60% Innovations in DIabetes from the US, face to face meeting, scientific Forums
– Integration with R&D Obesity as a complication of Diabetes, gate relations, Academia sees Pharma as friend, entrepreneurship from Academia — new direction – this is the successful adoptation
#startup#science#partnerships#biotech#pharmanews#venturecapital
|
@SachsAssociates@pharma_BI@BiotechNews |
Leave a Reply